Time to Culture Conversion and Regimen Composition in Multidrug-Resistant Tuberculosis Treatment

Sputum cultures are an important tool in monitoring the response to tuberculosis treatment, especially in multidrug-resistant tuberculosis. There has, however, been little study of the effect of treatment regimen composition on culture conversion. Well-designed clinical trials of new anti-tuberculosis drugs require this information to establish optimized background regimens for comparison. We conducted a retrospective cohort study to assess whether the use of an aggressive multidrug-resistant tuberculosis regimen was associated with more rapid sputum culture conversion. We conducted Cox proportional-hazards analyses to examine the relationship between receipt of an aggressive regimen for the 14 prior consecutive days and sputum culture conversion. Sputum culture conversion was achieved in 519 (87.7%) of the 592 patients studied. Among patients who had sputum culture conversion, the median time to conversion was 59 days (IQR: 31–92). In 480 patients (92.5% of those with conversion), conversion occurred within the first six months of treatment. Exposure to an aggressive regimen was independently associated with sputum culture conversion during the first six months of treatment (HR: 1.36; 95% CI: 1.10, 1.69). Infection with human immunodeficiency virus (HR 3.36; 95% CI: 1.47, 7.72) and receiving less exposure to tuberculosis treatment prior to the individualized multidrug-resistant tuberculosis regimen (HR: 1.58; 95% CI: 1.28, 1.95) were also independently positively associated with conversion. Tachycardia (HR: 0.77; 95% CI: 0.61, 0.98) and respiratory difficulty (HR: 0.78; 95% CI: 0.62, 0.97) were independently associated with a lower rate of conversion. This study is the first demonstrating that the composition of the multidrug-resistant tuberculosis treatment regimen influences the time to culture conversion. These results support the use of an aggressive regimen as the optimized background regimen in trials of new anti-TB drugs.

[1]  M. Becerra,et al.  Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. , 2011, The International Journal of Tuberculosis and Lung Disease.

[2]  D. Dowdy,et al.  Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[3]  J. Avorn.  Approval of a tuberculosis drug based on a paradoxical surrogate measure. , 2013, JAMA.

[4]  H S F Fraser,et al.  Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. , 2005, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[5]  A. Rouillon,et al.  Transmission of tubercle bacilli: The effects of chemotherapy. , 1976, Tubercle.

[6]  Sonya S. Shin,et al.  Aggressive regimens for multidrug-resistant tuberculosis reduce recurrence. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  Gavin Churchyard,et al.  The diarylquinoline TMC207 for multidrug-resistant tuberculosis. , 2009, The New England journal of medicine.

[8]  I. Haq,et al.  Predictors of Two Months Culture Conversion in Multidrug-Resistant Tuberculosis: Findings from a Retrospective Cohort Study , 2014, PloS one.

[9]  Gerhard Walzl,et al.  Baseline Predictors of Sputum Culture Conversion in Pulmonary Tuberculosis: Importance of Cavities, Smoking, Time to Detection and W-Beijing Genotype , 2012, PloS one.

[10]  K. Narayan,et al.  Diabetes Mellitus, Smoking Status, and Rate of Sputum Culture Conversion in Patients with Multidrug-Resistant Tuberculosis: A Cohort Study from the Country of Georgia , 2014, PloS one.

[11]  Gee Young Suh,et al.  Delamanid for multidrug-resistant pulmonary tuberculosis. , 2012, The New England journal of medicine.

[12]  John L. Johnson,et al.  Impact of human immunodeficiency virus type-1 infection on the initial bacteriologic and radiographic manifestations of pulmonary tuberculosis in Uganda. Makerere University-Case Western Reserve University Research Collaboration. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[13]  Terry M. Therneau,et al.  Extending the Cox Model , 1997 .

[14]  Hamish S. F. Fraser,et al.  Aggressive Regimens for Multidrug-Resistant Tuberculosis Decrease All-Cause Mortality , 2013, PloS one.

[15]  E. Kurbatova,et al.  Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[16]  Sonya S. Shin,et al.  Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and death. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  L. Tanoue.  Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis , 2009 .

[18]  Paul Farmer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet. Programmes and Principles in Treatment of Multidrug-resistant Tuberculosis , 2022 .

[19]  U. Lalloo,et al.  Culture Conversion Among HIV Co-Infected Multidrug-Resistant Tuberculosis Patients in Tugela Ferry, South Africa , 2011, PloS one.

[20]  W. Burman.  Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Dreher.  Modeling Survival Data Extending The Cox Model , 2016 .

[22]  M. Heo,et al.  Chest Radiograph Findings and Time to Culture Conversion in Patients with Multidrug-Resistant Tuberculosis and HIV in Tugela Ferry, South Africa , 2013, PLoS ONE.

[23]  H. Schünemann,et al.  The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis , 2011 .

[24]  R. Wallis,et al.  Sustainable tuberculosis drug development. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  E. Kurbatova,et al.  Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.